You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOlanzapine
Accession NumberDB00334  (APRD00138)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionOlanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.
Structure
Thumb
Synonyms
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Olanzapin
Olanzapina
Olanzapine
Olanzapinum
Zyprexa
External Identifiers
  • LY 170053
  • UNII-X7S6Q4MHCB
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-olanzapine ODTtablet (orally disintegrating)5 mgoralBgp Pharma Ulc2014-09-172015-12-31Canada
Abbott-olanzapine ODTtablet (orally disintegrating)10 mgoralAbbott Laboratories, Limited2014-09-172015-12-31Canada
Abbott-olanzapine ODTtablet (orally disintegrating)15 mgoralAbbott Laboratories2014-12-032015-12-31Canada
Accel-olanzapinetablet2.5 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapinetablet10 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapinetablet5 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapinetablet15 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Accel-olanzapinetablet20 mgoralAccel Pharma IncNot applicableNot applicableCanada
Accel-olanzapinetablet7.5 mgoralAccel Pharma Inc2014-09-042015-11-09Canada
Act Olanzapinetablet20 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet5 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet7.5 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet10 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet2.5 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapinetablet15 mgoralActavis Pharma Company2009-10-15Not applicableCanada
Act Olanzapine ODTtablet (orally disintegrating)20 mgoralActavis Pharma Company2009-10-16Not applicableCanada
Act Olanzapine ODTtablet (orally disintegrating)5 mgoralActavis Pharma Company2009-10-16Not applicableCanada
Act Olanzapine ODTtablet (orally disintegrating)10 mgoralActavis Pharma Company2009-10-16Not applicableCanada
Act Olanzapine ODTtablet (orally disintegrating)15 mgoralActavis Pharma Company2009-10-16Not applicableCanada
Auro-olanzapine ODTtablet (orally disintegrating)15 mgoralAuro Pharma Inc2015-12-01Not applicableCanada
Auro-olanzapine ODTtablet (orally disintegrating)20 mgoralAuro Pharma Inc2015-12-01Not applicableCanada
Auro-olanzapine ODTtablet (orally disintegrating)5 mgoralAuro Pharma Inc2015-12-01Not applicableCanada
Auro-olanzapine ODTtablet (orally disintegrating)10 mgoralAuro Pharma Inc2015-12-01Not applicableCanada
Ava-olanzapinetablet7.5 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapinetablet10.0 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapinetablet2.5 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapinetablet15.0 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-olanzapinetablet5.0 mgoralAvanstra Inc2011-11-232014-08-21Canada
Dom-olanzapinetablet5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapinetablet7.5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapinetablet10 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapinetablet15 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapinetablet2.5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapine ODTtablet (orally disintegrating)5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapine ODTtablet (orally disintegrating)10 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-olanzapine ODTtablet (orally disintegrating)15 mgoralDominion PharmacalNot applicableNot applicableCanada
Ipg-olanzapinetablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet2.5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet15 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapinetablet7.5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTtablet (orally disintegrating)5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTtablet (orally disintegrating)10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTtablet (orally disintegrating)15 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-olanzapine ODTtablet (orally disintegrating)20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp Olanzapine Fctablet15 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet2.5 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet20 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet5 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet7.5 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine Fctablet10 mgoralJamp Pharma Corporation2015-06-05Not applicableCanada
Jamp Olanzapine ODTtablet (orally disintegrating)15 mgoralJamp Pharma Corporation2014-08-01Not applicableCanada
Jamp Olanzapine ODTtablet (orally disintegrating)20 mgoralJamp Pharma Corporation2014-08-01Not applicableCanada
Jamp Olanzapine ODTtablet (orally disintegrating)5 mgoralJamp Pharma Corporation2014-08-01Not applicableCanada
Jamp Olanzapine ODTtablet (orally disintegrating)10 mgoralJamp Pharma Corporation2014-08-01Not applicableCanada
Mar-olanzapinetablet7.5 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapinetablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-olanzapinetablet10 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapinetablet2.5 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapinetablet15 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapinetablet5 mgoralMarcan Pharmaceuticals Inc2014-11-17Not applicableCanada
Mar-olanzapine ODTtablet (orally disintegrating)15 mgoralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mar-olanzapine ODTtablet (orally disintegrating)20 mgoralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mar-olanzapine ODTtablet (orally disintegrating)5 mgoralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mar-olanzapine ODTtablet (orally disintegrating)10 mgoralMarcan Pharmaceuticals Inc2013-05-16Not applicableCanada
Mint-olanzapinetablet15 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet2.5 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet20 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet5 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet7.5 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapinetablet10 mgoralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-olanzapine ODTtablet (orally disintegrating)20 mgoralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mint-olanzapine ODTtablet (orally disintegrating)5 mgoralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mint-olanzapine ODTtablet (orally disintegrating)10 mgoralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mint-olanzapine ODTtablet (orally disintegrating)15 mgoralMint Pharmaceuticals Inc2015-03-18Not applicableCanada
Mylan-olanzapinetablet5 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapinetablet20 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapinetablet7.5 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapinetablet10 mgoralMylan Pharmaceuticals Ulc2010-05-16Not applicableCanada
Mylan-olanzapinetablet15 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapinetablet2.5 mgoralMylan Pharmaceuticals Ulc2010-06-15Not applicableCanada
Mylan-olanzapine ODTtablet (orally disintegrating)20 mgoralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Mylan-olanzapine ODTtablet (orally disintegrating)5 mgoralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Mylan-olanzapine ODTtablet (orally disintegrating)10 mgoralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Mylan-olanzapine ODTtablet (orally disintegrating)15 mgoralMylan Pharmaceuticals Ulc2012-03-30Not applicableCanada
Ntp-olanzapinetablet7.5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapinetablet10.0 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapinetablet15.0 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapinetablet2.5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-olanzapinetablet5.0 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-olanzapinetablet2.5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapinetablet15.0 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapinetablet5.0 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapinetablet7.5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-olanzapinetablet10.0 mgoralNu Pharm IncNot applicableNot applicableCanada
Olanzapinetablet7.5 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet20 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet15 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet7.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet10 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet10 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet10 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet7.5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet5 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet2.5 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2013-07-22Not applicableUs
Olanzapinetablet10 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet2.5 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet2.5 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet10 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet15 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet15 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet2.5 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet15 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet10 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet7.5 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet5 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet5 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet5 mg/1oralREMEDYREPACK INC.2013-04-29Not applicableUs
Olanzapinetablet15 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet15 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet2.5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet5 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet2.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet5 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapinetablet20 mgoralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
Olanzapinetablet15 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet10 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet7.5 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Olanzapinetablet7.5 mgoralNovopharm LimitedNot applicableNot applicableCanada
Olanzapinetablet7.5 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapinetablet20 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapinetablet2.5 mgoralSanis Health Inc2011-10-26Not applicableCanada
Olanzapinetablet5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Olanzapinetablet20 mgoralPro Doc Limitee2014-06-10Not applicableCanada
Olanzapine for Injectionpowder for solution10 mgintramuscularSandoz Canada Incorporated2014-07-22Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)10 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapine ODTtablet (orally disintegrating)15 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)5 mgoralSanis Health Inc2011-10-07Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)5 mgoralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)20 mgoralSanis Health IncNot applicableNot applicableCanada
Olanzapine ODTtablet (orally disintegrating)15 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapine ODTtablet (orally disintegrating)10 mgoralSanis Health Inc2011-10-07Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)20 mgoralPro Doc Limitee2014-06-10Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)10 mgoralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)5 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)15 mgoralSanis Health Inc2011-10-07Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)15 mgoralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)5 mgoralMeliapharm Inc2011-10-182014-06-25Canada
Olanzapine ODTtablet (orally disintegrating)10 mgoralPro Doc Limitee2010-02-01Not applicableCanada
Olanzapine ODTtablet (orally disintegrating)20 mgoralSivem Pharmaceuticals Ulc2012-04-24Not applicableCanada
Olanzapine-odttablet (orally disintegrating)5 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine-odttablet (orally disintegrating)10 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine-odttablet (orally disintegrating)15 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Olanzapine-odttablet (orally disintegrating)20 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
PHL-olanzapinetablet2.5 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapinetablet15 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapinetablet5 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapinetablet7.5 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapinetablet10 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapine ODTtablet (orally disintegrating)5 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapine ODTtablet (orally disintegrating)10 mgoralPharmel Inc2010-02-18Not applicableCanada
PHL-olanzapine ODTtablet (orally disintegrating)15 mgoralPharmel Inc2010-02-18Not applicableCanada
PMS-olanzapinetablet5 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapinetablet7.5 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapinetablet20 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-olanzapinetablet10 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapinetablet15 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapinetablet2.5 mgoralPharmascience Inc2008-04-02Not applicableCanada
PMS-olanzapine ODTtablet (orally disintegrating)20 mgoralPharmascience Inc2014-07-29Not applicableCanada
PMS-olanzapine ODTtablet (orally disintegrating)5 mgoralPharmascience Inc2009-10-15Not applicableCanada
PMS-olanzapine ODTtablet (orally disintegrating)10 mgoralPharmascience Inc2009-10-15Not applicableCanada
PMS-olanzapine ODTtablet (orally disintegrating)15 mgoralPharmascience Inc2009-10-15Not applicableCanada
Ran-olanzapinetablet7.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapinetablet10.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapinetablet2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapinetablet15.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapinetablet5.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-olanzapine Irtablet7.5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet2.5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet15 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine Irtablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Ran-olanzapine ODTtablet (orally disintegrating)5 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Ran-olanzapine ODTtablet (orally disintegrating)10 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Ran-olanzapine ODTtablet (orally disintegrating)15 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Ran-olanzapine ODTtablet (orally disintegrating)20 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-10-17Not applicableCanada
Riva-olanzapinetablet7.5 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapinetablet10 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapinetablet2.5 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapinetablet15 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapinetablet5 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTtablet (orally disintegrating)20 mgoralLaboratoire Riva Inc2014-06-12Not applicableCanada
Riva-olanzapine ODTtablet (orally disintegrating)5 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTtablet (orally disintegrating)10 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Riva-olanzapine ODTtablet (orally disintegrating)15 mgoralLaboratoire Riva Inc2010-02-17Not applicableCanada
Sandoz Olanzapinetablet2.5 mgoralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz Olanzapinetablet15.0 mgoralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz Olanzapinetablet5.0 mgoralSandoz Canada Incorporated2009-12-06Not applicableCanada
Sandoz Olanzapinetablet20.0 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Olanzapinetablet7.5 mgoralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz Olanzapinetablet10.0 mgoralSandoz Canada Incorporated2009-06-12Not applicableCanada
Sandoz Olanzapine ODTtablet (orally disintegrating)15 mgoralSandoz Canada Incorporated2010-02-26Not applicableCanada
Sandoz Olanzapine ODTtablet (orally disintegrating)20 mgoralSandoz Canada Incorporated2010-02-26Not applicableCanada
Sandoz Olanzapine ODTtablet (orally disintegrating)5 mgoralSandoz Canada Incorporated2010-02-26Not applicableCanada
Sandoz Olanzapine ODTtablet (orally disintegrating)10 mgoralSandoz Canada Incorporated2010-02-26Not applicableCanada
Teva-olanzapinetablet7.5 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapinetablet10 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapinetablet2.5 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapinetablet15 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapinetablet5 mgoralTeva Canada Limited2007-06-06Not applicableCanada
Teva-olanzapinetablet20 mgoralTeva Canada Limited2011-04-28Not applicableCanada
Teva-olanzapine ODtablet (orally disintegrating)20 mgoralTeva Canada Limited2010-03-082016-01-18Canada
Teva-olanzapine ODtablet (orally disintegrating)15 mgoralTeva Canada Limited2010-03-082016-01-18Canada
Teva-olanzapine ODTtablet (orally disintegrating)5 mgoralTeva Canada Limited2010-03-08Not applicableCanada
Teva-olanzapine ODTtablet (orally disintegrating)10 mgoralTeva Canada Limited2010-03-08Not applicableCanada
Torrent-olanzapine ODTtablet (orally disintegrating)5 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-olanzapine ODTtablet (orally disintegrating)10 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-olanzapine ODTtablet (orally disintegrating)15 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-olanzapine ODTtablet (orally disintegrating)20 mgoralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-olanzapinetablet2.5 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapinetablet15 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapinetablet5.0 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapinetablet7.5 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapinetablet10 mgoralVanc Pharmaceuticals Inc2015-07-10Not applicableCanada
Van-olanzapine ODTtablet (orally disintegrating)20 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-olanzapine ODTtablet (orally disintegrating)5 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-olanzapine ODTtablet (orally disintegrating)10 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
Van-olanzapine ODTtablet (orally disintegrating)15 mgoralVanc Pharmaceuticals IncNot applicableNot applicableCanada
ZypadheraPowder and solvent for prolonged release suspension for injection300 mgIntramuscular useEli Lilly Nederland B.V.2008-11-19Not applicableEu
ZypadheraPowder and solvent for prolonged release suspension for injection405 mgIntramuscular useEli Lilly Nederland B.V.2008-11-19Not applicableEu
ZypadheraPowder and solvent for prolonged release suspension for injection210 mgIntramuscular useEli Lilly Nederland B.V.2008-11-19Not applicableEu
ZyprexaCoated tablet7.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet2.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-07-12Not applicableUs
Zyprexatablet10 mg/1oralPd Rx Pharmaceuticals, Inc.1996-10-01Not applicableUs
ZyprexaCoated tablet20 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet7.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet2.5 mg/1oralEli Lilly and Company1997-06-23Not applicableUs
Zyprexatablet5 mg/1oralRebel Distributors Corp1996-10-01Not applicableUs
Zyprexatablet2.5 mg/1oralPhysicians Total Care, Inc.2003-08-20Not applicableUs
ZyprexaPowder for solution for injection10 mgIntramuscular useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet15 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet5 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-30Not applicableUs
Zyprexatablet10 mg/1oralDispensing Solutions, Inc.1996-10-01Not applicableUs
ZyprexaCoated tablet7.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet10 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet15 mg/1oralEli Lilly and Company2000-01-10Not applicableUs
Zyprexatablet5 mg/1oralREMEDYREPACK INC.2013-04-102016-04-05Us
ZyprexaCoated tablet15 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet2.5 mg/1oralbryant ranch prepack1997-06-23Not applicableUs
ZyprexaCoated tablet2.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet10 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet5 mg/1oralEli Lilly and Company1996-10-01Not applicableUs
Zyprexatablet10 mg/1oralRebel Distributors Corp1996-10-01Not applicableUs
Zyprexatablet7.5 mg/1oralPhysicians Total Care, Inc.2005-06-14Not applicableUs
Zyprexatablet2.5 mg/1oralH.J. Harkins Company, Inc.1997-06-23Not applicableUs
Zyprexatablet15 mg/1oralDispensing Solutions, Inc.2000-01-10Not applicableUs
ZyprexaCoated tablet2.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet20 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet20 mg/1oralEli Lilly and Company2001-03-01Not applicableUs
Zyprexatablet15 mg/1oralREMEDYREPACK INC.2013-05-142016-04-05Us
ZyprexaCoated tablet10 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet15 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet20 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet7.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet2.5 mg/1oralDispensing Solutions, Inc.1997-06-23Not applicableUs
ZyprexaCoated tablet2.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet15 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet7.5 mg/1oralEli Lilly and Company1996-10-01Not applicableUs
Zyprexatablet20 mg/1oralRebel Distributors Corp2001-03-01Not applicableUs
Zyprexatablet5 mg/1oralCardinal Health1996-10-01Not applicableUs
Zyprexatablet10 mg/1oralPhysicians Total Care, Inc.2003-06-20Not applicableUs
ZyprexaCoated tablet5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet2.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet20 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet20 mg/1oralREMEDYREPACK INC.2013-07-082016-04-05Us
Zyprexatablet2.5 mg/1oralCardinal Health1997-06-23Not applicableUs
ZyprexaCoated tablet10 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaPowder for solution for injection10 mgIntramuscular useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet10 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-30Not applicableUs
Zyprexatablet5 mg/1oralDispensing Solutions, Inc.1996-10-01Not applicableUs
ZyprexaCoated tablet5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet7.5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet20 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet10 mg/1oralEli Lilly and Company1996-10-01Not applicableUs
Zyprexatablet10 mg/1oralREMEDYREPACK INC.2013-04-102016-04-05Us
Zyprexatablet10 mg/1oralCardinal Health1996-10-01Not applicableUs
ZyprexaCoated tablet15 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
ZyprexaCoated tablet5 mgOral useEli Lilly Nederland B.V.1996-09-27Not applicableEu
Zyprexatablet5 mg/1oralSTAT Rx USA LLC1996-10-01Not applicableUs
Zyprexatablet5 mg/1oralPhysicians Total Care, Inc.2003-09-30Not applicableUs
Zyprexa -2.5mgtablet2.5 mgoralEli Lilly Canada Inc1997-12-08Not applicableCanada
Zyprexa -7.5mgtablet7.5 mgoralEli Lilly Canada Inc1996-11-04Not applicableCanada
Zyprexa - 10mgtablet10 mgoralEli Lilly Canada Inc1996-11-14Not applicableCanada
Zyprexa - 5mgtablet5 mgoralEli Lilly Canada Inc1996-11-14Not applicableCanada
Zyprexa 15mgtablet15 mgoralEli Lilly Canada Inc2002-06-24Not applicableCanada
Zyprexa 20mgtablet20 mgoralEli Lilly Canada Inc2007-04-30Not applicableCanada
Zyprexa Intramuscularpowder for solution10 mgintramuscularEli Lilly Canada Inc2004-01-12Not applicableCanada
Zyprexa Intramuscularinjection, powder, for solution10 mg/2mLintramuscularEli Lilly and Company2004-04-01Not applicableUs
Zyprexa RelprevvkitintramuscularEli Lilly and Company2010-03-01Not applicableUs
Zyprexa RelprevvkitintramuscularEli Lilly and Company2010-03-01Not applicableUs
Zyprexa RelprevvkitintramuscularEli Lilly and Company2010-03-01Not applicableUs
Zyprexa VelotabOrodispersible tablet20 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet15 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet20 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet20 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet5 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet20 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet5 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet20 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet5 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet5 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet5 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet10 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet10 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet10 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet10 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet15 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet10 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet15 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet15 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa VelotabOrodispersible tablet15 mgOral useEli Lilly Nederland B.V.2000-02-03Not applicableEu
Zyprexa Zydistablet, orally disintegrating10 mg/1oralEli Lilly and Company2000-06-01Not applicableUs
Zyprexa Zydistablet (orally disintegrating)20 mgoralEli Lilly Canada Inc2007-01-02Not applicableCanada
Zyprexa Zydistablet, orally disintegrating10 mg/1oralCardinal Health2000-06-01Not applicableUs
Zyprexa Zydistablet (orally disintegrating)5 mgoralEli Lilly Canada Inc2001-03-06Not applicableCanada
Zyprexa Zydistablet, orally disintegrating15 mg/1oralEli Lilly and Company2001-09-01Not applicableUs
Zyprexa Zydistablet, orally disintegrating5 mg/1oralCardinal Health2000-06-01Not applicableUs
Zyprexa Zydistablet (orally disintegrating)10 mgoralEli Lilly Canada Inc2001-03-15Not applicableCanada
Zyprexa Zydistablet, orally disintegrating20 mg/1oralEli Lilly and Company2001-09-01Not applicableUs
Zyprexa Zydistablet, orally disintegrating5 mg/1oralEli Lilly and Company2000-06-01Not applicableUs
Zyprexa Zydistablet (orally disintegrating)15 mgoralEli Lilly Canada Inc2004-01-09Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olanzapinetablet15.0 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet5.0 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet20.0 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet7.5 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet10.0 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapinetablet2.5 mgoralApotex Inc2009-10-09Not applicableCanada
Apo-olanzapine ODTtablet (orally disintegrating)15 mgoralApotex Inc2011-08-08Not applicableCanada
Apo-olanzapine ODTtablet (orally disintegrating)20 mgoralApotex Inc2011-08-08Not applicableCanada
Apo-olanzapine ODTtablet (orally disintegrating)5 mgoralApotex Inc2011-11-16Not applicableCanada
Apo-olanzapine ODTtablet (orally disintegrating)10 mgoralApotex Inc2011-08-08Not applicableCanada
Olanzapinetablet, film coated7.5 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralAv Pak2014-04-17Not applicableUs
Olanzapinetablet, film coated10 mg/1oralProficient Rx LP2012-04-23Not applicableUs
Olanzapinetablet10 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet10 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralCardinal Health2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralPrasco Laboratories2011-10-25Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
Olanzapinetablet10 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralApotex Corp.2011-10-24Not applicableUs
Olanzapinetablet, film coated5 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2015-12-30Not applicableUs
Olanzapinetablet5 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, film coated20 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2013-04-01Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2014-02-03Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralTYA Pharmaceuticals2012-02-28Not applicableUs
Olanzapinetablet, film coated20 mg/1oralDr.Reddy's laboratories Ltd.2012-04-23Not applicableUs
Olanzapinetablet5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralPrasco Laboratories2014-05-15Not applicableUs
Olanzapinetablet, film coated5 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralREMEDYREPACK INC.2015-05-26Not applicableUs
Olanzapinetablet15 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet, film coated7.5 mg/1oralDr.Reddy's Laboratories Inc2013-12-10Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-01-04Not applicableUs
Olanzapinetablet5 mg/1oralTYA Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralPhysicians Total Care, Inc.2012-08-22Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralAurobindo Pharma Limited2014-05-15Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralCardinal Health2012-02-17Not applicableUs
Olanzapinetablet7.5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, film coated15 mg/1oralAmerican Health Packaging2012-02-01Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralAmerican Health Packaging2016-01-01Not applicableUs
Olanzapinetablet2.5 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet7.5 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
Olanzapinetablet, film coated20 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet5 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated10 mg/1oralProficient Rx LP2011-10-24Not applicableUs
Olanzapinetablet2.5 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet2.5 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
Olanzapinetablet20 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
Olanzapinetablet2.5 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet, film coated20 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated20 mg/1oralREMEDYREPACK INC.2015-11-17Not applicableUs
Olanzapinetablet20 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralTeva Pharmaceuticals USA Inc2012-01-24Not applicableUs
Olanzapinetablet, film coated15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2015-12-30Not applicableUs
Olanzapinetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet, film coated5 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet20 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated20 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralAv Pak2014-04-17Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralProficient Rx LP2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet15 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralPrasco Laboratories2011-10-25Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralApotex Corp.2011-10-24Not applicableUs
Olanzapinetablet, film coated10 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet, film coated7.5 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2015-08-06Not applicableUs
Olanzapinetablet20 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet7.5 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralTeva Pharmaceuticals USA Inc2012-02-17Not applicableUs
Olanzapinetablet, film coated5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
Olanzapinetablet5 mg/1oralREMEDYREPACK INC.2013-04-01Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
Olanzapinetablet15 mg/1oralREMEDYREPACK INC.2014-02-06Not applicableUs
Olanzapineinjection, powder, lyophilized, for solution10 mg/2mLintramuscularTYA Pharmaceuticals2012-06-27Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
Olanzapinetablet7.5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralPrasco Laboratories2014-05-15Not applicableUs
Olanzapinetablet, film coated10 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet, film coated10 mg/1oralDr.Reddy's Laboratories Inc2013-12-10Not applicableUs
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2013-03-28Not applicableUs
Olanzapinetablet10 mg/1oralTYA Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralPhysicians Total Care, Inc.2012-08-22Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralAurobindo Pharma Limited2014-05-15Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralCardinal Health2012-02-17Not applicableUs
Olanzapinetablet10 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated15 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, film coated20 mg/1oralAmerican Health Packaging2012-02-01Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralAmerican Health Packaging2016-01-01Not applicableUs
Olanzapinetablet5 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet10 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapineinjection, powder, for solution10 mg/2mLintramuscularSandoz Inc2011-10-24Not applicableUs
Olanzapinetablet7.5 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
Olanzapinetablet, film coated20 mg/1oralProficient Rx LP2011-10-24Not applicableUs
Olanzapinetablet5 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet5 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralPrasco Laboratories2011-10-25Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
Olanzapinetablet5 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralApotex Corp.2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralAvera Mc Kennan Hospital2015-04-22Not applicableUs
Olanzapinetablet, film coated20 mg/1oralREMEDYREPACK INC.2015-11-20Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralAvera Mc Kennan Hospital2015-09-02Not applicableUs
Olanzapinetablet, film coated5 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet20 mg/1oralAscend Laboratories, LLC2012-01-01Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralAmerican Health Packaging2016-01-01Not applicableUs
Olanzapinetablet, film coated15 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet2.5 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated15 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapinetablet, film coated10 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralAv Pak2014-04-17Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralbryant ranch prepack2011-10-24Not applicableUs
Olanzapinetablet20 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet20 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet2.5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
Olanzapinetablet10 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralPrasco Laboratories2014-05-15Not applicableUs
Olanzapinetablet, film coated10 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralREMEDYREPACK INC.2015-10-19Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralREMEDYREPACK INC.2016-01-07Not applicableUs
Olanzapinetablet10 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralTeva Pharmaceuticals USA Inc2012-02-17Not applicableUs
Olanzapinetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
Olanzapinetablet, film coated5 mg/1oralREMEDYREPACK INC.2014-04-23Not applicableUs
Olanzapineinjection, powder, for solution10 mg/2mLintramuscularTYA Pharmaceuticals2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
Olanzapinetablet, film coated5 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated15 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet, film coated5 mg/1oralREMEDYREPACK INC.2013-04-22Not applicableUs
Olanzapinetablet5 mg/1oralREMEDYREPACK INC.2013-04-01Not applicableUs
Olanzapinetablet15 mg/1oralTYA Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralDr.Reddy's Laboratories Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralAurobindo Pharma Limited2014-05-15Not applicableUs
Olanzapinetablet, film coated10 mg/1oralClinical Solutions Wholesale, Llc2012-04-23Not applicableUs
Olanzapinetablet15 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated20 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralAmerican Health Packaging2014-05-01Not applicableUs
Olanzapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2014-08-07Not applicableUs
Olanzapinetablet7.5 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet15 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2012-12-13Not applicableUs
Olanzapinetablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2011-10-24Not applicableUs
Olanzapineinjection, powder, for solution10 mg/2mLintramuscularSandoz Inc2011-10-24Not applicableUs
Olanzapinetablet10 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralRebel Distributors Corp2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralAv Pak2014-04-17Not applicableUs
Olanzapinetablet, film coated5 mg/1oralProficient Rx LP2014-08-22Not applicableUs
Olanzapinetablet7.5 mg/1oralLucid Pharma Llc2014-09-26Not applicableUs
Olanzapinetablet7.5 mg/1oralAurobindo Pharma Limited2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralPrasco Laboratories2011-10-25Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralJubilant Cadista Pharmaceuticals Inc2012-09-13Not applicableUs
Olanzapinetablet7.5 mg/1oralAscend Laboratories, LLC2012-01-02Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralApotex Corp.2011-10-24Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet, film coated5 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Olanzapinetablet, film coated15 mg/1oralPhysicians Total Care, Inc.2012-07-02Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralAurobindo Pharma Limited2014-05-15Not applicableUs
Olanzapinetablet, film coated10 mg/1oralCardinal Health2012-04-23Not applicableUs
Olanzapinetablet5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated7.5 mg/1oralGolden State Medical Supply, Inc.2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralAmerican Health Packaging2016-01-01Not applicableUs
Olanzapinetablet, film coated20 mg/1oralMylan Institutional Inc.2012-06-082015-12-29Us
Olanzapinetablet5 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralMylan Pharmaceuticals Inc.2014-05-12Not applicableUs
Olanzapinetablet, film coated15 mg/1oralMajor Pharmaceuticals2012-04-23Not applicableUs
Olanzapinetablet, film coated5 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet, film coated5 mg/1oralDr.Reddy's Laboratories Inc2013-12-10Not applicableUs
Olanzapinetablet10 mg/1oralREMEDYREPACK INC.2013-03-29Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralTYA Pharmaceuticals2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating10 mg/1oralPar Pharmaceutical, Inc.2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralSun Pharmaceutical Industries Limited2012-02-28Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-06-05Not applicableUs
Olanzapinetablet, film coated5 mg/1oralTYA Pharmaceuticals2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralDr.Reddy's Laboratories Limited2011-10-24Not applicableUs
Olanzapinetablet15 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated15 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralPrasco Laboratories2014-05-15Not applicableUs
Olanzapinetablet, film coated15 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet, film coated15 mg/1oralDispensing Solutions, Inc.2011-10-24Not applicableUs
Olanzapinetablet20 mg/1oralREMEDYREPACK INC.2015-10-19Not applicableUs
Olanzapinetablet15 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapinetablet, orally disintegrating15 mg/1oralTeva Pharmaceuticals USA Inc2012-01-24Not applicableUs
Olanzapinetablet, film coated20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-10-24Not applicableUs
Olanzapinetablet2.5 mg/1oralTorrent Pharmaceuticals Limited2012-04-23Not applicableUs
Olanzapinetablet, orally disintegrating20 mg/1oralMacleods Pharmaceuticals Limited2015-02-27Not applicableUs
Olanzapineinjection, powder, lyophilized, for solution10 mg/2mLintramuscularAmerican Regent, Inc.2012-06-27Not applicableUs
Olanzapinetablet, orally disintegrating5 mg/1oralTorrent Pharmaceuticals Limited2011-10-25Not applicableUs
Olanzapinetablet, film coated20 mg/1oralMacleods Pharmaceuticals Limited2014-08-22Not applicableUs
Olanzapinetablet, film coated5 mg/1oralREMEDYREPACK INC.2013-05-01Not applicableUs
Olanzapinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-01-212016-04-05Us
Olanzapinetablet, orally disintegrating5 mg/1oralTYA Pharmaceuticals2012-02-28Not applicableUs
Olanzapinetablet, film coated15 mg/1oralDr.Reddy's laboratories Ltd.2012-04-23Not applicableUs
Olanzapinetablet2.5 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated20 mg/1oralClinical Solutions Wholesale2011-10-24Not applicableUs
Olanzapinetablet20 mg/1oralPrasco Laboratories2012-04-23Not applicableUs
Olanzapinetablet, film coated2.5 mg/1oralApotex Corp.2012-04-23Not applicableUs
Olanzapinetablet, film coated10 mg/1oralAmerican Health Packaging2014-05-01Not applicableUs
Olanzapinetablet, film coated20 mg/1oralREMEDYREPACK INC.2014-08-07Not applicableUs
Olanzapinetablet10 mg/1oralCitron Pharma LLC2012-04-232015-12-29Us
Olanzapinetablet20 mg/1oralSun Pharmaceutical Industries Limited2012-04-23Not applicableUs
Olanzapinetablet2.5 mg/1oralQilu Pharmaceutical Co., Ltd.2016-01-27Not applicableUs
Olanzapine ApotexOrodispersible tablet5 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexFilm-coated tablet5 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexOrodispersible tablet10 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexFilm-coated tablet10 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexOrodispersible tablet20 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexFilm-coated tablet5 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexOrodispersible tablet10 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexOrodispersible tablet10 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexFilm-coated tablet10 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexFilm-coated tablet5 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexFilm-coated tablet7.5 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexOrodispersible tablet15 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexOrodispersible tablet5 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexFilm-coated tablet2.5 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexFilm-coated tablet10 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexFilm-coated tablet7.5 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexOrodispersible tablet20 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine ApotexOrodispersible tablet5 mgOral useApotex Europe B.V.  2010-06-10Not applicableEu
Olanzapine GlenmarkTablet15 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet7.5 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet2.5 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet10 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet15 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet7.5 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet5 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet10 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet2.5 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet20 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet7.5 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet5 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet15 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet2.5 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet20 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet10 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine GlenmarkTablet5 mgOral useGlenmark Pharmaceuticals Europe Limited2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet20 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet10 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet5 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet15 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet10 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet5 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet20 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet15 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet5 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet20 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet15 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine Glenmark EuropeOrodispersible tablet10 mgOral useGlenmark Pharmaceuticals Europe Limited  2009-12-03Not applicableEu
Olanzapine TevaFilm-coated tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet7.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet7.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet2.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet7.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet2.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet7.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet7.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet2.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet2.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet7.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet7.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet2.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet2.5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet10 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet5 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaFilm-coated tablet15 mgOral useTeva Pharma2007-12-12Not applicableEu
Olanzapine TevaOrodispersible tablet20 mgOral useTeva Pharma2007-12-12Not applicableEu
OlazaxTablet10 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
OlazaxTablet15 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
OlazaxTablet5 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
OlazaxTablet20 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
OlazaxTablet7.5 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-11Not applicableEu
Olazax DisperziOrodispersible tablet5 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
Olazax DisperziOrodispersible tablet20 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
Olazax DisperziOrodispersible tablet7.5 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
Olazax DisperziOrodispersible tablet10 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
Olazax DisperziOrodispersible tablet15 mgOral useGlenmark Pharmaceuticals S.R.O.  2009-12-10Not applicableEu
ZalastaTablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet2.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet15 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet2.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet15 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet2.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet15 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet2.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet15 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet15 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet7.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet20 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet2.5 mgOral useKrka2007-09-27Not applicableEu
ZalastaTablet10 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet5 mgOral useKrka2007-09-27Not applicableEu
ZalastaOrodispersible tablet15 mgOral useKrka2007-09-27Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Olanzapine NeopharmaCoated Tablet10 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet2.5 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet7.5 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet10 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet2.5 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet7.5 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet15 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet5 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet10 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet15 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
Olanzapine NeopharmaCoated Tablet5 mgOral useCipla (Eu) Limited2007-11-14Not applicableEu
International Brands
NameCompany
AedonG.L. Pharma
AmulsinSanitas
ApiscoLKM
ApsicoLKM
ArkolamylMylan
CaprilonLavipharm
CO OlanzapineCobalt
DeprexSquare
DominazolStein
DopinDaksh
EgolanzaEGIS
ElynzaElynza
FrenialBiogen
Jolyon-MDLupin
KozylexQuisisana
LanopinMolekule
LanzapinBiogened
LanzepRenata
LapenzaSmart Intermed
LapozanMedochemie
LazapixPortfarma
Brand mixtures
NameLabellerIngredients
Olanzapine and FluoxetineTeva Pharmaceuticals USA Inc
SymbyaxEli Lilly and Company
Salts
Name/CASStructureProperties
Olanzapine pamoate
ThumbNot applicableDBSALT001064
Categories
UNIIN7U69T4SZR
CAS number132539-06-1
WeightAverage: 312.432
Monoisotopic: 312.14086735
Chemical FormulaC17H20N4S
InChI KeyInChIKey=KVWDHTXUZHCGIO-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
IUPAC Name
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),5,8,10,12-hexaene
SMILES
CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub ClassNot Available
Direct ParentBenzodiazepines
Alternative Parents
Substituents
  • Benzodiazepine
  • Thieno-para-diazepine
  • 2,3,5-trisubstituted thiophene
  • N-alkylpiperazine
  • N-methylpiperazine
  • Para-diazepine
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Heteroaromatic compound
  • Thiophene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Secondary amine
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients.
PharmacodynamicsOlanzapine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, olanzapine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.
Mechanism of actionOlanzapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
Related Articles
AbsorptionWell absorbed, with approximately 40% of the dose metabolized before reaching the systemic circulation.
Volume of distribution
  • 1000 L
Protein binding93%
Metabolism

Hepatic

SubstrateEnzymesProduct
Olanzapine
7-hydroxyolanzapineDetails
Olanzapine
4'-N-desmethylolanzapineDetails
Olanzapine
2-hydroxymethylolanzapineDetails
Route of eliminationIt is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized before reaching the systemic circulation. Following a single oral dose of 14C labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized.
Half life21 to 54 hours
Clearance
  • 12 to 47 L/h
ToxicitySymptoms of an overdose include tachycardia, agitation, dysarthria, decreased consciousness and coma. Death has been reported after an acute overdose of 0.45g, but also survival after an acute overdose of 1500g.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
5-hydroxytryptamine receptor 1A
Gene symbol: HTR1A
UniProt: P08908
rs6295 Not AvailableCC Allele (homozygous)Associated with the ability to ameliorate impaired attention in patients with schizophrenia.20533011
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9645
Blood Brain Barrier+0.9652
Caco-2 permeable+0.5993
P-glycoprotein substrateSubstrate0.8524
P-glycoprotein inhibitor IInhibitor0.6888
P-glycoprotein inhibitor IIInhibitor0.7204
Renal organic cation transporterInhibitor0.7715
CYP450 2C9 substrateNon-substrate0.7493
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5421
CYP450 1A2 substrateInhibitor0.6454
CYP450 2C9 inhibitorNon-inhibitor0.6914
CYP450 2D6 inhibitorInhibitor0.608
CYP450 2C19 inhibitorInhibitor0.572
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.707
Ames testNon AMES toxic0.7009
CarcinogenicityNon-carcinogens0.9369
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Inhibitor0.7569
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Tabletoral10.0 mg
Tabletoral15.0 mg
Tabletoral20.0 mg
Tabletoral5.0 mg
Injection, powder, lyophilized, for solutionintramuscular10 mg/2mL
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral2.5 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral5 mg/1
Tablet, film coatedoral7.5 mg/1
Film-coated tabletOral use10 mg
Film-coated tabletOral use2.5 mg
Film-coated tabletOral use5 mg
Film-coated tabletOral use7.5 mg
Orodispersible tabletOral use10 mg
Orodispersible tabletOral use15 mg
Orodispersible tabletOral use20 mg
Orodispersible tabletOral use5 mg
TabletOral use10 mg
TabletOral use15 mg
TabletOral use2.5 mg
TabletOral use20 mg
TabletOral use5 mg
TabletOral use7.5 mg
Coated tabletOral use10 mg
Coated tabletOral use15 mg
Coated tabletOral use2.5 mg
Coated tabletOral use5 mg
Coated tabletOral use7.5 mg
Film-coated tabletOral use15 mg
Film-coated tabletOral use20 mg
Orodispersible tabletOral use7.5 mg
Capsuleoral
Powder and solvent for prolonged release suspension for injectionIntramuscular use210 mg
Powder and solvent for prolonged release suspension for injectionIntramuscular use300 mg
Powder and solvent for prolonged release suspension for injectionIntramuscular use405 mg
Coated tabletOral use20 mg
Powder for solution for injectionIntramuscular use10 mg
Tabletoral10 mg/1
Tabletoral15 mg/1
Tabletoral2.5 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Tabletoral7.5 mg/1
Tabletoral2.5 mg
Tabletoral7.5 mg
Tabletoral10 mg
Tabletoral5 mg
Tabletoral15 mg
Tabletoral20 mg
Injection, powder, for solutionintramuscular10 mg/2mL
Powder for solutionintramuscular10 mg
Kitintramuscular
Tablet (orally disintegrating)oral10 mg
Tablet (orally disintegrating)oral15 mg
Tablet (orally disintegrating)oral20 mg
Tablet (orally disintegrating)oral5 mg
Tablet, orally disintegratingoral10 mg/1
Tablet, orally disintegratingoral15 mg/1
Tablet, orally disintegratingoral20 mg/1
Tablet, orally disintegratingoral5 mg/1
Prices
Unit descriptionCostUnit
Zyprexa relprevv 405 mg vial1287.9USD vial
Zyprexa relprevv 300 mg vial954.0USD vial
Zyprexa relprevv 210 mg vial667.8USD vial
ZyPREXA Zydis 30 10 mg Dispersible Tablet Box562.35USD box
ZyPREXA Zydis 30 5 mg Dispersible Tablet Box385.63USD box
Zyprexa 10 mg vial35.69USD vial
Zyprexa zydis 20 mg tablet34.87USD tablet
Zyprexa 20 mg tablet34.37USD tablet
Zyprexa zydis 15 mg tablet26.45USD tablet
Zyprexa 15 mg tablet21.14USD tablet
Symbyax 12-25 mg capsule20.62USD capsule
Symbyax 12-50 mg capsule20.62USD capsule
Zyprexa zydis 10 mg tablet18.02USD tablet
Symbyax 6-50 mg capsule14.56USD capsule
Zyprexa 10 mg tablet14.09USD tablet
Symbyax 6-25 mg capsule13.69USD capsule
Zyprexa zydis 5 mg tablet12.36USD tablet
Zyprexa 7.5 mg tablet11.23USD tablet
Symbyax 3-25 mg capsule10.01USD capsule
Zyprexa 5 mg tablet8.92USD tablet
Zyprexa Zydis 10 mg Disintegrating Tablet7.86USD tablet
Zyprexa 2.5 mg tablet7.1USD tablet
Apo-Olanzapine 15 mg Tablet6.64USD tablet
Co Olanzapine 15 mg Tablet6.64USD tablet
Novo-Olanzapine 15 mg Tablet6.64USD tablet
Pms-Olanzapine 15 mg Tablet6.64USD tablet
Apo-Olanzapine 10 mg Tablet4.43USD tablet
Co Olanzapine 10 mg Tablet4.43USD tablet
Novo-Olanzapine 10 mg Tablet4.43USD tablet
Pms-Olanzapine 10 mg Tablet4.43USD tablet
Zyprexa Zydis 5 mg Disintegrating Tablet3.93USD tablet
Co Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Novo-Olanzapine Od 10 mg Disintegrating Tablet3.54USD tablet
Pms-Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Sandoz Olanzapine Odt 10 mg Disintegrating Tablet3.54USD tablet
Apo-Olanzapine 7.5 mg Tablet3.32USD tablet
Co Olanzapine 7.5 mg Tablet3.32USD tablet
Novo-Olanzapine 7.5 mg Tablet3.32USD tablet
Pms-Olanzapine 7.5 mg Tablet3.32USD tablet
Apo-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine 5 mg Tablet2.21USD tablet
Novo-Olanzapine 5 mg Tablet2.21USD tablet
Pms-Olanzapine 5 mg Tablet2.21USD tablet
Co Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Novo-Olanzapine Od 5 mg Disintegrating Tablet1.77USD tablet
Pms-Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Sandoz Olanzapine Odt 5 mg Disintegrating Tablet1.77USD tablet
Apo-Olanzapine 2.5 mg Tablet1.11USD tablet
Co Olanzapine 2.5 mg Tablet1.11USD tablet
Novo-Olanzapine 2.5 mg Tablet1.11USD tablet
Pms-Olanzapine 2.5 mg Tablet1.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2041113 No1998-07-142011-04-24Canada
CA2216372 No2007-11-202016-03-22Canada
US5229382 No1994-04-232011-04-23Us
US5945416 No1997-03-242017-03-24Us
US6169084 No1998-09-302018-09-30Us
US6251895 No1998-03-232018-03-23Us
US6960577 No1997-11-012017-11-01Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point195 °CNot Available
logP2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0942 mg/mLALOGPS
logP3.61ALOGPS
logP3.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.17ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area30.87 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity93.87 m3·mol-1ChemAxon
Polarizability35.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Charles Arthur Bunnell, Samuel Dean Larsen, John Richard Nichols, Susan Marie Reutzel, Gregory Alan Stephenson, “Intermediates and process for preparing olanzapine.” U.S. Patent US6020487, issued September, 1996.

US6020487
General References
  1. de Haan L, van Amelsvoort T, Rosien K, Linszen D: Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl). 2004 Sep;175(3):389-90. [PubMed:15322727 ]
  2. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 1;59(3):211-5. Epub 2005 Sep 1. [PubMed:16139813 ]
  3. Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006 Feb;26(1):45-9. [PubMed:16415705 ]
  4. Jakovljevic M, Sagud M, Mihaljevic-Peles A: Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports. Acta Psychiatr Scand. 2003 May;107(5):394-6; discussion 396. [PubMed:12752037 ]
  5. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003 May 1;61(1):7-18. [PubMed:12648731 ]
External Links
ATC CodesN05AH03
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (251 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineOlanzapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineOlanzapine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Olanzapine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Olanzapine.
AbirateroneThe serum concentration of Olanzapine can be increased when it is combined with Abiraterone.
AcarboseOlanzapine may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Olanzapine.
AcenocoumarolOlanzapine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Olanzapine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Olanzapine.
AcetaminophenThe serum concentration of Olanzapine can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Olanzapine.
Acetylsalicylic acidOlanzapine may increase the antiplatelet activities of Acetylsalicylic acid.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Olanzapine.
AfatinibThe serum concentration of Olanzapine can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Olanzapine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Olanzapine.
AlbendazoleThe serum concentration of Olanzapine can be increased when it is combined with Albendazole.
AlbiglutideOlanzapine may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Olanzapine can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Olanzapine can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Olanzapine.
AlfentanilAlfentanil may increase the serotonergic activities of Olanzapine.
AlfentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Olanzapine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Olanzapine.
AlogliptinOlanzapine may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Olanzapine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alprazolam.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Olanzapine.
AmantadineThe serum concentration of Olanzapine can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Olanzapine can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Olanzapine can be decreased when it is combined with Amiodarone.
AmiodaroneOlanzapine may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olanzapine.
AmlodipineThe serum concentration of Olanzapine can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Olanzapine.
AmoxapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Olanzapine.
AmphetamineOlanzapine may decrease the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Olanzapine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Olanzapine can be increased when it is combined with Amsacrine.
AnagrelideOlanzapine may increase the QTc-prolonging activities of Anagrelide.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Olanzapine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Olanzapine.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Olanzapine.
Arsenic trioxideOlanzapine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherOlanzapine may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Olanzapine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Olanzapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Olanzapine.
AstemizoleThe serum concentration of Olanzapine can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Olanzapine.
AtazanavirThe serum concentration of Olanzapine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Olanzapine.
AtomoxetineThe metabolism of Olanzapine can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Olanzapine can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Olanzapine.
AzelastineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Olanzapine.
AzithromycinOlanzapine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Olanzapine can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Olanzapine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Olanzapine.
BedaquilineOlanzapine may increase the QTc-prolonging activities of Bedaquiline.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Olanzapine.
BendroflumethiazideOlanzapine may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Olanzapine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Olanzapine.
BenzphetamineOlanzapine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Olanzapine.
BepridilThe serum concentration of Olanzapine can be increased when it is combined with Bepridil.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Olanzapine.
BetaxololThe metabolism of Olanzapine can be decreased when combined with Betaxolol.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Olanzapine.
BezitramideBezitramide may increase the serotonergic activities of Olanzapine.
BiperidenThe serum concentration of Olanzapine can be increased when it is combined with Biperiden.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Olanzapine.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Olanzapine.
BortezomibThe metabolism of Olanzapine can be decreased when combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Olanzapine.
BosutinibThe serum concentration of Olanzapine can be increased when it is combined with Bosutinib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Olanzapine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
BrimonidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Bromazepam.
BromocriptineOlanzapine may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Olanzapine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Olanzapine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Olanzapine.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Olanzapine.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Olanzapine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Olanzapine.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Olanzapine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Olanzapine.
BuprenorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Buprenorphine.
BupropionThe metabolism of Olanzapine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Olanzapine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Olanzapine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Olanzapine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Olanzapine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Olanzapine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Olanzapine.
ButorphanolButorphanol may increase the serotonergic activities of Olanzapine.
ButorphanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butorphanol.
CabazitaxelThe serum concentration of Olanzapine can be increased when it is combined with Cabazitaxel.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Olanzapine.
CaffeineThe serum concentration of Olanzapine can be increased when it is combined with Caffeine.
CanagliflozinOlanzapine may increase the hypoglycemic activities of Canagliflozin.
CanagliflozinThe serum concentration of Olanzapine can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Olanzapine can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Olanzapine can be increased when it is combined with Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Olanzapine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Olanzapine.
CarfentanilCarfentanil may increase the serotonergic activities of Olanzapine.
CarfentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Olanzapine.
CaroxazoneCaroxazone may increase the serotonergic activities of Olanzapine.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Olanzapine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Olanzapine.
CaspofunginThe serum concentration of Olanzapine can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Olanzapine.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Olanzapine.
CefpodoximeOlanzapine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
CefuroximeOlanzapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
CelecoxibThe metabolism of Olanzapine can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Olanzapine.
CeritinibOlanzapine may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Olanzapine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Olanzapine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Olanzapine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Olanzapine.
ChloroquineOlanzapine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Olanzapine can be increased when it is combined with Chloroquine.
ChlorothiazideOlanzapine may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Olanzapine.
ChlorphentermineOlanzapine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Olanzapine.
ChlorpromazineOlanzapine may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideOlanzapine may increase the hypoglycemic activities of Chlorpropamide.
ChlorpropamideThe serum concentration of Olanzapine can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Olanzapine.
ChlorthalidoneOlanzapine may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Olanzapine.
CholecalciferolThe metabolism of Olanzapine can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Olanzapine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Olanzapine can be decreased when it is combined with Cholic Acid.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Olanzapine.
CilazaprilThe serum concentration of Olanzapine can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Olanzapine.
CimetidineThe serum concentration of Olanzapine can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Olanzapine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Olanzapine.
CiprofloxacinOlanzapine may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Olanzapine can be increased when it is combined with Ciprofloxacin.
CisaprideOlanzapine may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Olanzapine is combined with Citalopram.
ClarithromycinOlanzapine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Olanzapine can be increased when it is combined with Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Olanzapine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Olanzapine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Olanzapine.
ClofazimineThe serum concentration of Olanzapine can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Olanzapine.
ClomipramineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Olanzapine.
ClorazepateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Clorazepate.
ClotrimazoleThe serum concentration of Olanzapine can be decreased when it is combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Olanzapine.
ClozapineOlanzapine may increase the QTc-prolonging activities of Clozapine.
CobicistatThe serum concentration of Olanzapine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Olanzapine.
CodeineCodeine may increase the serotonergic activities of Olanzapine.
CodeineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Codeine.
ColchicineThe serum concentration of Olanzapine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Olanzapine can be increased when it is combined with Colforsin.
CrizotinibOlanzapine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe serum concentration of Olanzapine can be increased when it is combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Olanzapine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olanzapine.
CyclophosphamideThe serum concentration of Olanzapine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Olanzapine can be decreased when it is combined with Cyclosporine.
CyproheptadineThe therapeutic efficacy of Olanzapine can be decreased when used in combination with Cyproheptadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Olanzapine.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Olanzapine.
DaclatasvirThe serum concentration of Olanzapine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Olanzapine can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Olanzapine.
DapagliflozinOlanzapine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Olanzapine.
DapoxetineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dapoxetine.
DapoxetineDapoxetine may increase the serotonergic activities of Olanzapine.
DarifenacinThe metabolism of Olanzapine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Olanzapine can be increased when it is combined with Darunavir.
DasatinibOlanzapine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DasatinibThe serum concentration of Olanzapine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Olanzapine can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Olanzapine can be increased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Olanzapine.
DelavirdineThe metabolism of Olanzapine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Olanzapine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Olanzapine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Olanzapine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Olanzapine.
DesmopressinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Olanzapine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Olanzapine.
DexamethasoneThe serum concentration of Olanzapine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olanzapine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Olanzapine.
DexmethylphenidateOlanzapine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineOlanzapine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanOlanzapine may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Olanzapine.
DextromoramideDextromoramide may increase the serotonergic activities of Olanzapine.
DextromoramideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dextromoramide.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Olanzapine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dextropropoxyphene.
DezocineDezocine may increase the serotonergic activities of Olanzapine.
DezocineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diazepam.
DiclofenacThe serum concentration of Olanzapine can be increased when it is combined with Diclofenac.
DicoumarolOlanzapine may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Olanzapine.
DigoxinThe serum concentration of Olanzapine can be decreased when it is combined with Digoxin.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Olanzapine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Olanzapine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Olanzapine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydroetorphine.
DihydromorphineDihydromorphine may increase the serotonergic activities of Olanzapine.
DihydromorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydromorphine.
DiltiazemThe serum concentration of Olanzapine can be increased when it is combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Olanzapine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Olanzapine.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Olanzapine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Olanzapine can be increased when it is combined with Dipyridamole.
DisopyramideOlanzapine may increase the hypoglycemic activities of Disopyramide.
DofetilideOlanzapine may increase the QTc-prolonging activities of Dofetilide.
DolasetronOlanzapine may increase the QTc-prolonging activities of Dolasetron.
DomperidoneOlanzapine may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Olanzapine.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Olanzapine.
DoxazosinThe serum concentration of Olanzapine can be increased when it is combined with Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Olanzapine.
DoxorubicinThe serum concentration of Olanzapine can be decreased when it is combined with Doxorubicin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
DoxylamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Doxylamine.
DPDPEDPDPE may increase the serotonergic activities of Olanzapine.
DPDPEThe risk or severity of adverse effects can be increased when Olanzapine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
DronedaroneThe serum concentration of Olanzapine can be increased when it is combined with Dronedarone.
DronedaroneOlanzapine may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Olanzapine.
DroperidolOlanzapine may increase the QTc-prolonging activities of Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Olanzapine.
DulaglutideOlanzapine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Olanzapine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Olanzapine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Olanzapine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Olanzapine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Olanzapine.
ElbasvirThe serum concentration of Olanzapine can be increased when it is combined with Elbasvir.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Olanzapine.
EliglustatOlanzapine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Olanzapine can be decreased when combined with Eliglustat.
EmpagliflozinOlanzapine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilThe serum concentration of Olanzapine can be increased when it is combined with Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Olanzapine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Olanzapine.
EnzalutamideThe serum concentration of Olanzapine can be increased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Olanzapine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Olanzapine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Olanzapine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Olanzapine.
ErythromycinOlanzapine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe serum concentration of Olanzapine can be decreased when it is combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Olanzapine is combined with Escitalopram.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Olanzapine.
EstazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Estazolam.
EstramustineThe serum concentration of Olanzapine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Olanzapine can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Olanzapine can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Olanzapine.
EthanolOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Olanzapine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Olanzapine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Olanzapine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Olanzapine.
Ethyl biscoumacetateOlanzapine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Olanzapine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Olanzapine.
EthylmorphineEthylmorphine may increase the serotonergic activities of Olanzapine.
EthylmorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Olanzapine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Olanzapine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Olanzapine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Olanzapine.
EtoperidoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etoperidone.
EtoperidoneEtoperidone may increase the serotonergic activities of Olanzapine.
EtoposideThe serum concentration of Olanzapine can be increased when it is combined with Etoposide.
EtorphineEtorphine may increase the serotonergic activities of Olanzapine.
EtorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etorphine.
EtravirineThe serum concentration of Olanzapine can be increased when it is combined with Etravirine.
ExenatideOlanzapine may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Olanzapine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Olanzapine.
FelodipineThe serum concentration of Olanzapine can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Olanzapine.
FenfluramineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fenfluramine.
FenfluramineFenfluramine may increase the serotonergic activities of Olanzapine.
FentanylFentanyl may increase the serotonergic activities of Olanzapine.
FentanylThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Olanzapine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Olanzapine.
FidaxomicinThe serum concentration of Olanzapine can be increased when it is combined with Fidaxomicin.
FlecainideOlanzapine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Olanzapine.
FluconazoleThe serum concentration of Olanzapine can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Olanzapine.
FlumazenilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flumazenil.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Olanzapine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Olanzapine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Olanzapine.
FlurazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Olanzapine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Olanzapine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Olanzapine.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Olanzapine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Olanzapine.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Olanzapine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Olanzapine.
FurazolidoneFurazolidone may increase the serotonergic activities of Olanzapine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Olanzapine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Olanzapine.
Gadobenic acidOlanzapine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Olanzapine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Olanzapine.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Olanzapine.
GefitinibThe serum concentration of Olanzapine can be increased when it is combined with Gefitinib.
GemifloxacinOlanzapine may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Olanzapine can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Olanzapine.
GliclazideOlanzapine may increase the hypoglycemic activities of Gliclazide.
GlimepirideOlanzapine may increase the hypoglycemic activities of Glimepiride.
GlipizideOlanzapine may increase the hypoglycemic activities of Glipizide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Olanzapine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Olanzapine.
GlyburideOlanzapine may increase the hypoglycemic activities of Glyburide.
GlyburideThe serum concentration of Olanzapine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Olanzapine can be increased when it is combined with Glycerol.
GoserelinOlanzapine may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Olanzapine can be increased when it is combined with Gramicidin D.
GranisetronOlanzapine may increase the QTc-prolonging activities of Granisetron.
GrepafloxacinThe serum concentration of Olanzapine can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Olanzapine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Olanzapine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Olanzapine.
HaloperidolOlanzapine may increase the QTc-prolonging activities of Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Olanzapine.
HeroinHeroin may increase the serotonergic activities of Olanzapine.
HeroinThe risk or severity of adverse effects can be increased when Olanzapine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Olanzapine.
HydracarbazineHydracarbazine may increase the serotonergic activities of Olanzapine.
HydrochlorothiazideOlanzapine may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Olanzapine.
HydrocodoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Olanzapine can be increased when it is combined with Hydrocortisone.
HydroflumethiazideOlanzapine may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Olanzapine.
HydromorphoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideOlanzapine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
HydroxyzineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Hydroxyzine.
IbutilideOlanzapine may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Olanzapine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Olanzapine.
ImatinibThe serum concentration of Olanzapine can be increased when it is combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olanzapine.
IndalpineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Indalpine.
IndalpineIndalpine may increase the serotonergic activities of Olanzapine.
IndapamideOlanzapine may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Olanzapine.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Olanzapine.
IndomethacinThe serum concentration of Olanzapine can be increased when it is combined with Indomethacin.
Insulin AspartOlanzapine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirOlanzapine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineOlanzapine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineOlanzapine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanOlanzapine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproOlanzapine may increase the hypoglycemic activities of Insulin Lispro.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Olanzapine.
Ioflupane I-123Olanzapine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IproclozideIproclozide may increase the serotonergic activities of Olanzapine.
IproniazidIproniazid may increase the serotonergic activities of Olanzapine.
IsavuconazoniumThe serum concentration of Olanzapine can be increased when it is combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Olanzapine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Olanzapine.
IsoniazidThe metabolism of Olanzapine can be decreased when combined with Isoniazid.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Olanzapine.
ItraconazoleThe serum concentration of Olanzapine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Olanzapine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Olanzapine can be increased when it is combined with Ivermectin.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Olanzapine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Olanzapine.
KetobemidoneKetobemidone may increase the serotonergic activities of Olanzapine.
KetobemidoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Olanzapine.
KetoconazoleThe serum concentration of Olanzapine can be increased when it is combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Olanzapine.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Olanzapine.
LamotrigineLamotrigine may increase the sedative activities of Olanzapine.
LamotrigineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lamotrigine.
LanreotideOlanzapine may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Olanzapine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Olanzapine can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Olanzapine.
LenvatinibOlanzapine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideOlanzapine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Olanzapine.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Olanzapine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Olanzapine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Olanzapine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Olanzapine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Olanzapine.
LevofloxacinOlanzapine may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Olanzapine can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Olanzapine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levomilnacipran.
LevorphanolLevorphanol may increase the serotonergic activities of Olanzapine.
LevorphanolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levorphanol.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Olanzapine.
LevothyroxineThe serum concentration of Olanzapine can be decreased when it is combined with Levothyroxine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Olanzapine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine.
LinezolidLinezolid may increase the serotonergic activities of Olanzapine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Olanzapine.
LiothyronineThe serum concentration of Olanzapine can be decreased when it is combined with Liothyronine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Olanzapine.
LiotrixThe serum concentration of Olanzapine can be decreased when it is combined with Liotrix.
LiraglutideOlanzapine may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineOlanzapine may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Olanzapine can be increased when it is combined with Lisinopril.
LithiumLithium may increase the neurotoxic activities of Olanzapine.
LithiumThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lithium.
LofentanilLofentanil may increase the serotonergic activities of Olanzapine.
LofentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lofentanil.
LomitapideThe serum concentration of Olanzapine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Olanzapine can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Olanzapine can be increased when it is combined with Lopinavir.
LopinavirOlanzapine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Olanzapine.
LorazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Lorazepam.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Olanzapine.
LosartanThe serum concentration of Olanzapine can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Olanzapine can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Olanzapine.
Lu AA21004The risk or severity of adverse effects can be increased when Olanzapine is combined with Lu AA21004.
LumacaftorThe serum concentration of Olanzapine can be decreased when it is combined with Lumacaftor.
LumefantrineOlanzapine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Olanzapine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Olanzapine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Olanzapine.
MebanazineMebanazine may increase the serotonergic activities of Olanzapine.
MebendazoleThe serum concentration of Olanzapine can be increased when it is combined with Mebendazole.
MecaserminOlanzapine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Olanzapine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Olanzapine.
MefloquineThe serum concentration of Olanzapine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Olanzapine can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Olanzapine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Olanzapine.
MephentermineOlanzapine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Olanzapine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Olanzapine.
MequitazineOlanzapine may increase the arrhythmogenic activities of Mequitazine.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Olanzapine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Olanzapine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Olanzapine.
MetforminOlanzapine may increase the hypoglycemic activities of Metformin.
MethadoneMethadone may increase the serotonergic activities of Olanzapine.
MethadoneOlanzapine may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Olanzapine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methadyl Acetate.
MethamphetamineOlanzapine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Olanzapine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Olanzapine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Olanzapine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Olanzapine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Olanzapine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Olanzapine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Olanzapine.
MethyclothiazideOlanzapine may increase the hyponatremic activities of Methyclothiazide.
Methylene blueOlanzapine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Olanzapine.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Olanzapine.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Olanzapine.
MetolazoneOlanzapine may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Olanzapine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Olanzapine.
MetyrosineOlanzapine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Olanzapine.
MibefradilThe serum concentration of Olanzapine can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Olanzapine can be increased when it is combined with Miconazole.
MidazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Midazolam.
MifepristoneOlanzapine may increase the hypoglycemic activities of Mifepristone.
MifepristoneThe serum concentration of Olanzapine can be decreased when it is combined with Mifepristone.
MiglitolOlanzapine may increase the hypoglycemic activities of Miglitol.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Olanzapine.
MilnacipranThe risk or severity of adverse effects can be increased when Olanzapine is combined with Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Olanzapine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
MirabegronThe metabolism of Olanzapine can be decreased when combined with Mirabegron.
MirtazapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Olanzapine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Olanzapine.
MitomycinThe serum concentration of Olanzapine can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Olanzapine can be decreased when it is combined with Mitoxantrone.
MoclobemideMoclobemide may increase the serotonergic activities of Olanzapine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Olanzapine.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Olanzapine.
MorphineMorphine may increase the serotonergic activities of Olanzapine.
MorphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Morphine.
MoxifloxacinOlanzapine may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.
NabiloneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Olanzapine.
NalbuphineNalbuphine may increase the serotonergic activities of Olanzapine.
NalbuphineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nalbuphine.
NaltrexoneThe serum concentration of Olanzapine can be increased when it is combined with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Olanzapine.
NaringeninThe serum concentration of Olanzapine can be increased when it is combined with Naringenin.
NateglinideOlanzapine may increase the hypoglycemic activities of Nateglinide.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Olanzapine.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Olanzapine.
NeostigmineThe serum concentration of Olanzapine can be increased when it is combined with Neostigmine.
NevirapineThe metabolism of Olanzapine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Olanzapine.
NicardipineThe serum concentration of Olanzapine can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Olanzapine can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Olanzapine.
NilotinibThe serum concentration of Olanzapine can be increased when it is combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Olanzapine.
NisoldipineThe serum concentration of Olanzapine can be increased when it is combined with Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nitrazepam.
NitrendipineThe serum concentration of Olanzapine can be increased when it is combined with Nitrendipine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Olanzapine.
NorethisteroneThe serum concentration of Olanzapine can be decreased when it is combined with Norethisterone.
NormethadoneNormethadone may increase the serotonergic activities of Olanzapine.
NormethadoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Olanzapine.
OctamoxinOctamoxin may increase the serotonergic activities of Olanzapine.
OctreotideOlanzapine may increase the hypoglycemic activities of Octreotide.
OfloxacinOlanzapine may increase the QTc-prolonging activities of Ofloxacin.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Olanzapine.
OmeprazoleThe serum concentration of Olanzapine can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Olanzapine.
OndansetronOlanzapine may increase the QTc-prolonging activities of Ondansetron.
OpiumOpium may increase the serotonergic activities of Olanzapine.
OpiumThe risk or severity of adverse effects can be increased when Olanzapine is combined with Opium.
OrphenadrineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Olanzapine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Olanzapine.
OsimertinibThe serum concentration of Olanzapine can be decreased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Olanzapine.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Olanzapine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Olanzapine.
OxycodoneOxycodone may increase the serotonergic activities of Olanzapine.
OxycodoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxycodone.
OxymorphoneOxymorphone may increase the serotonergic activities of Olanzapine.
OxymorphoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxymorphone.
P-NitrophenolThe serum concentration of Olanzapine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Olanzapine can be increased when it is combined with Paclitaxel.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Olanzapine.
Palmitic AcidThe serum concentration of Olanzapine can be increased when it is combined with Palmitic Acid.
PanobinostatOlanzapine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Olanzapine can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Olanzapine can be increased when it is combined with Pantoprazole.
ParaldehydeOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Olanzapine.
PargylinePargyline may increase the serotonergic activities of Olanzapine.
ParoxetineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Paroxetine.
PasireotideOlanzapine may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Olanzapine.
Peginterferon alfa-2bThe serum concentration of Olanzapine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Olanzapine.
PentamidineOlanzapine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Olanzapine.
PentazocineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Olanzapine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Olanzapine.
PerflutrenOlanzapine may increase the QTc-prolonging activities of Perflutren.
PerindoprilThe serum concentration of Olanzapine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Olanzapine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Olanzapine.
PethidinePethidine may increase the serotonergic activities of Olanzapine.
PethidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pethidine.
PhenelzinePhenelzine may increase the serotonergic activities of Olanzapine.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Olanzapine.
PhenindioneOlanzapine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Olanzapine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Olanzapine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Olanzapine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Olanzapine.
PhenprocoumonOlanzapine may increase the anticoagulant activities of Phenprocoumon.
PhentermineOlanzapine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Olanzapine.
PimozideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Olanzapine.
PioglitazoneOlanzapine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Olanzapine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Olanzapine.
PirenzepineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pirenzepine.
PirlindolePirlindole may increase the serotonergic activities of Olanzapine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Olanzapine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Olanzapine.
Platelet Activating FactorThe serum concentration of Olanzapine can be decreased when it is combined with Platelet Activating Factor.
PolythiazideOlanzapine may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Olanzapine.
PonatinibThe serum concentration of Olanzapine can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Olanzapine.
PosaconazoleThe serum concentration of Olanzapine can be increased when it is combined with Posaconazole.
PractololThe serum concentration of Practolol can be increased when it is combined with Olanzapine.
PramipexoleOlanzapine may increase the sedative activities of Pramipexole.
PramlintideOlanzapine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Olanzapine.
PravastatinThe serum concentration of Olanzapine can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Prazepam.
PrazosinThe serum concentration of Olanzapine can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Olanzapine can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Olanzapine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Olanzapine.
PrimaquineOlanzapine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Olanzapine.
ProbenecidThe serum concentration of Olanzapine can be increased when it is combined with Probenecid.
ProcainamideOlanzapine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Olanzapine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Olanzapine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olanzapine.
ProgesteroneThe serum concentration of Olanzapine can be decreased when it is combined with Progesterone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Olanzapine.
PromazineOlanzapine may increase the QTc-prolonging activities of Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Olanzapine.
PropafenoneOlanzapine may increase the QTc-prolonging activities of Propafenone.
PropafenoneThe serum concentration of Olanzapine can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Olanzapine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Olanzapine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Olanzapine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Olanzapine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olanzapine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Olanzapine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Olanzapine.
QuercetinThe serum concentration of Olanzapine can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Olanzapine.
QuinacrineThe serum concentration of Olanzapine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Olanzapine.
QuinethazoneOlanzapine may increase the hyponatremic activities of Quinethazone.
QuinidineThe serum concentration of Olanzapine can be increased when it is combined with Quinidine.
QuinidineOlanzapine may increase the QTc-prolonging activities of Quinidine.
QuinineOlanzapine may increase the hypoglycemic activities of Quinine.
QuinineThe serum concentration of Olanzapine can be increased when it is combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Olanzapine.
RanitidineThe serum concentration of Olanzapine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Olanzapine can be increased when it is combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Olanzapine.
ReboxetineThe serum concentration of Olanzapine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Olanzapine can be increased when it is combined with Regorafenib.
RemifentanilRemifentanil may increase the serotonergic activities of Olanzapine.
RemifentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Olanzapine.
RepaglinideOlanzapine may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Olanzapine.
RifampicinThe serum concentration of Olanzapine can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Olanzapine.
RilpivirineThe serum concentration of Olanzapine can be increased when it is combined with Rilpivirine.
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Olanzapine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Olanzapine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Olanzapine.
RitonavirThe serum concentration of Olanzapine can be decreased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Olanzapine.
RolapitantThe serum concentration of Olanzapine can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Olanzapine.
RopiniroleOlanzapine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Olanzapine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Olanzapine.
RosiglitazoneOlanzapine may increase the hypoglycemic activities of Rosiglitazone.
RotigotineOlanzapine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Olanzapine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Olanzapine.
SafrazineSafrazine may increase the serotonergic activities of Olanzapine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Olanzapine.
SaquinavirThe serum concentration of Olanzapine can be decreased when it is combined with Saquinavir.
SaxagliptinOlanzapine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Olanzapine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Olanzapine.
SelegilineSelegiline may increase the serotonergic activities of Olanzapine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Olanzapine.
SertralineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olanzapine.
SimeprevirThe serum concentration of Olanzapine can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Olanzapine can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Olanzapine can be decreased when it is combined with Sirolimus.
SitagliptinOlanzapine may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Olanzapine.
SorafenibThe serum concentration of Olanzapine can be increased when it is combined with Sorafenib.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Olanzapine.
SpironolactoneThe serum concentration of Olanzapine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Olanzapine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Olanzapine can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Olanzapine.
StreptozocinThe serum concentration of Olanzapine can be decreased when it is combined with Streptozocin.
SufentanilSufentanil may increase the serotonergic activities of Olanzapine.
SufentanilThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil.
SulfadiazineOlanzapine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleOlanzapine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Olanzapine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleOlanzapine may increase the hypoglycemic activities of Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Olanzapine.
SulpirideThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Olanzapine.
SunitinibOlanzapine may increase the hypoglycemic activities of Sunitinib.
SunitinibThe serum concentration of Olanzapine can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Olanzapine.
TacrineThe serum concentration of Olanzapine can be increased when it is combined with Tacrine.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Olanzapine.
TacrolimusThe serum concentration of Olanzapine can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Olanzapine can be decreased when it is combined with Tamoxifen.
TapentadolTapentadol may increase the serotonergic activities of Olanzapine.
TapentadolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Olanzapine.
Taurocholic AcidThe serum concentration of Olanzapine can be increased when it is combined with Taurocholic Acid.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Olanzapine.
TelavancinOlanzapine may increase the QTc-prolonging activities of Telavancin.
TelithromycinOlanzapine may increase the QTc-prolonging activities of Telithromycin.
TelmisartanThe serum concentration of Olanzapine can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Temazepam.
TemsirolimusThe serum concentration of Olanzapine can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Olanzapine can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Olanzapine can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Olanzapine can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Olanzapine can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Olanzapine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Olanzapine can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Olanzapine can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Olanzapine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Olanzapine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Olanzapine.
ThalidomideOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Olanzapine.
TheophyllineThe metabolism of Olanzapine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Olanzapine.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Olanzapine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Olanzapine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Olanzapine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Olanzapine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Olanzapine.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Olanzapine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Olanzapine.
TicagrelorThe serum concentration of Olanzapine can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Olanzapine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Olanzapine.
TimololThe serum concentration of Timolol can be increased when it is combined with Olanzapine.
TipranavirThe metabolism of Olanzapine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Olanzapine.
TolazamideOlanzapine may increase the hypoglycemic activities of Tolazamide.
TolbutamideOlanzapine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Olanzapine.
ToloxatoneToloxatone may increase the serotonergic activities of Olanzapine.
TolvaptanThe serum concentration of Olanzapine can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Olanzapine.
ToremifeneOlanzapine may increase the QTc-prolonging activities of Toremifene.
TramadolTramadol may increase the serotonergic activities of Olanzapine.
TramadolThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tramadol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Olanzapine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Olanzapine.
TranylcypromineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Olanzapine is combined with Triazolam.
TrichlormethiazideOlanzapine may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olanzapine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Olanzapine.
TrimethoprimThe serum concentration of Olanzapine can be decreased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olanzapine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Olanzapine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Olanzapine.
TroleandomycinThe serum concentration of Olanzapine can be increased when it is combined with Troleandomycin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Olanzapine.
VandetanibOlanzapine may increase the QTc-prolonging activities of Vandetanib.
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Olanzapine.
VemurafenibThe serum concentration of Olanzapine can be increased when it is combined with Vemurafenib.
VemurafenibOlanzapine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Olanzapine.
VerapamilThe serum concentration of Olanzapine can be decreased when it is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Olanzapine.
VilazodoneThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Olanzapine.
VinblastineThe serum concentration of Olanzapine can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Olanzapine can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Olanzapine can be increased when it is combined with Vinorelbine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Olanzapine.
VortioxetineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vortioxetine.
WarfarinOlanzapine may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Olanzapine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Olanzapine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Olanzapine.
ZimelidineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zimelidine.
ZimelidineThe serum concentration of Olanzapine can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Olanzapine.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Olanzapine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Olanzapine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Olanzapine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Olanzapine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Olanzapine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Olanzapine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Olanzapine.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. McDonald LM, Moran PM, Vythelingum GN, Joseph MH, Stephenson JD, Gray JA: Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning. Psychopharmacology (Berl). 2003 Sep;169(3-4):321-31. Epub 2002 Aug 9. [PubMed:14530903 ]
  2. Moresco RM, Cavallaro R, Messa C, Bravi D, Gobbo C, Galli L, Lucignani G, Colombo C, Rizzo G, Velona I, Smeraldi E, Fazio F: Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004 Sep;18(3):355-65. [PubMed:15358979 ]
  3. Sharpley AL, Attenburrow ME, Hafizi S, Cowen PJ: Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry. 2005 Apr;66(4):450-4. [PubMed:15816787 ]
  4. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8. [PubMed:16038601 ]
  5. Padin JF, Rodriguez MA, Dominguez E, Dopeso-Reyes IG, Buceta M, Cano E, Sotelo E, Brea J, Caruncho HJ, Isabel Cadavid M, Castro M, Isabel Loza M: Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells. Neuropharmacology. 2006 Sep;51(4):923-32. Epub 2006 Aug 14. [PubMed:16905159 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  9. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonistagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699 ]
  3. Weizman T, Pick CG, Backer MM, Rigai T, Bloch M, Schreiber S: The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol. 2003 Oct 8;478(2-3):155-9. [PubMed:14575800 ]
  4. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T: In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol. 2007 Aug;21(6):620-7. Epub 2006 Nov 8. [PubMed:17092971 ]
  5. Thacker SK, Perna MK, Ward JJ, Schaefer TL, Williams MT, Kostrzewa RM, Brown RW: The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur J Neurosci. 2006 Oct;24(7):2075-83. [PubMed:17067304 ]
  6. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK: DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006 Mar;163(3):529-31. [PubMed:16513877 ]
  7. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  8. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R: The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006 Jun;31(6):1310-7. [PubMed:16237394 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J: Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2006 Feb 14;71(4):521-9. Epub 2005 Dec 5. [PubMed:16336943 ]
  3. Overstreet DH, Knapp DJ, Breese GR: Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res. 2007 Sep;31(9):1473-81. Epub 2007 Jul 11. [PubMed:17624999 ]
  4. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J: No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. Epub 2006 Sep 19. [PubMed:16983399 ]
  5. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396 ]
  6. Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52. [PubMed:16952163 ]
  7. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A: The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005 Mar;20(2):101-3. [PubMed:15729086 ]
  3. Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL: Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9- diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. J Pharmacol Exp Ther. 2005 Dec;315(3):1265-77. Epub 2005 Sep 1. [PubMed:16141369 ]
  4. Altschuler EL, Kast RE: Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses. 2005;65(1):65-7. [PubMed:15893120 ]
  5. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  6. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  3. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  4. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  3. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO: Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999 May 4;37(1):107-22. [PubMed:10227113 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins.
Gene Name:
HTR5A
Uniprot ID:
P47898
Molecular Weight:
40254.69 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  3. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
  2. Goodman, Louis Sanford;Brunton, Laurence L.;Chabner, Bruce;Knollman, Bjorn (2011). The Pharmacological Basis of Therapeutics (12th ed.). McGraw-Hill Professional Publishing. [ISBN:978-0-07-162442-8 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. [PubMed:8822531 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87-96. [PubMed:8822531 ]
33. D(2L) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
unknown
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]
34. D(2S) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
unknown
References
  1. Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. doi: 10.1177/0269881107082944. Epub 2008 Feb 28. [PubMed:18308814 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000 Aug;39(2):127-53. [PubMed:10976659 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. [PubMed:10511917 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 02:26